@article {MIZAMTSIDI1263, author = {MARIA MIZAMTSIDI and KONSTANTINOS NASTOS and FAUSTO PALAZZO and VASILIS CONSTANTINIDES and ROBERTO DINA and MEGAN FARENDEN and GEORGE MASTORAKOS and IOANNIS VASSILIOU and MARIA GAZOULI}, title = {Association Between hsa-miR-30e Polymorphisms and Sporadic Primary Hyperparathyroidism Risk}, volume = {33}, number = {4}, pages = {1263--1269}, year = {2019}, doi = {10.21873/invivo.11598}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Almost 15\% of patients with sporadic primary hyperparathyroidism (sPHPT) present with multiple gland disease (MGD). The aim of this study was to investigate the potential role of two polymorphisms of the hsa-miR-30e, in sPHPT tumorigenesis. Patients and Methods: One-hundred twenty sPHPT patients, 77 presenting a single adenoma and 43 with MGD, and 54 healthy controls were genotyped. The SNPs were identified using the allele-specific PCR methodology, while the hsa-miR-30e expression was analyzed by real-time quantitative reverse transcriptase PCR. Results: Hsa-miR-30e expression was found to be significantly higher in patients with MGD compared to patients with single adenomas (p=0.0019), but no differences were found regarding specific genotype carriers. The genotype frequencies for ss178077483 and rs7556088 were significantly different between patients and healthy controls. Conclusion: Although the polymorphisms cannot be used as biomarkers for the differential diagnosis of MGD, hsa-miR-30e expression could potentially serve as a biomarker for this purpose.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/33/4/1263}, eprint = {https://iv.iiarjournals.org/content/33/4/1263.full.pdf}, journal = {In Vivo} }